Primary Hepatocellular Carcinoma Clinical Trial
Official title:
A Prospective Multicenter Randomized Controlled Open-label Trial of Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients
A multicentre, randomized, open-label, parallel-group, active controlled study.
Primary hepatocellular carcinoma (HCC) is one of the most common types of cancer and
accounts for significant morbidity and mortality worldwide. Notably, more than half of the
new HCC cases and deaths develop in China. Transarterial chemoembolization (TACE) has been
proposed as the first-line therapeutic strategy for the treatment of patients with
unresectable HCC. However, TACE has several limitations itself which might be potentially
associated with tumor metastasis and relapse.
Recent studies have demonstrated that arsenic trioxide (As2O3) can act as the first-line
therapeutic option in the treatment of acute promyelocytic leukemia. Thereafter, several
small studies in China showed promising clinical benefits when As2O3 is administrated among
the HCC patients. With these preliminary results, the investigators are planning to carry
out a multicenter randomized controlled trial through which to explore the potential
efficacy and safety of adjuvant As2O3 treatment for HCC patients.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00966251 -
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03614546 -
Clinical Trial of Radiotherapy in Treating Primary Hepatocellular Carcinoma
|
N/A | |
| Not yet recruiting |
NCT03672305 -
Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC
|
Early Phase 1 | |
| Not yet recruiting |
NCT06124001 -
Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01563484 -
Comparison of Liver and Renal Function After Transarterial Chemoembolization for Primary Hepatocellular Carcinoma With Iso-osmolar Contrast Media and Low Osmolar Contrast Media
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT05872841 -
H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis
|
Phase 2 | |
| Recruiting |
NCT05242757 -
Clinical Study of MAK Immune Cells in the Treatment of PHC
|
N/A | |
| Completed |
NCT01828762 -
Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy
|
N/A |